Search Medical Condition
Please enter condition
Please choose location

Maple Grove, Minnesota Clinical Trials

A listing of Maple Grove, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (79) clinical trials

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

RECD3126 is a double-blind, placebo-controlled, parallel-group, multicenter, multiregional, 52-week study to assess the efficacy and safety of rifaximin DR tablets for the induction of clinical remission and endoscopic response at 16 weeks followed by clinical and endoscopic remission after 52 weeks of continuous therapy in subjects with active moderate Crohn's ...

Phase

2.7 miles

Learn More »

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

This is a prospective, multi-center, open-label, single-sequence, 6-month, pharmacokinetic, safety and tolerability study of IGSC 20% in subjects with primary immunodeficiency. Approximately 50 subjects will be enrolled in order to have approximately 30 adult subjects and 12 to 15 pediatric subjects (age 2-16 years) completing treatment with subcutaneously administered IGSC ...

Phase

2.7 miles

Learn More »

ROBUST I Pilot Study

The study is designed to determine the safety and effectiveness for drug coated balloon (DCB). Up to 30 subjects will be enrolled and treated with the device at up to 3 clinical sites. Due to the significantly higher prevalence of strictures in men vs. women and the etiology of those ...

Phase N/A

3.7 miles

Learn More »

Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer

PRIMARY OBJECTIVES: I. Assess the efficacy of either single agent olaparib or the combination of cediranib (cediranib maleate) and olaparib, as measured by progression free survival (PFS), as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer. SECONDARY OBJECTIVES: I. Assess ...

Phase

3.87 miles

Learn More »

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

PRIMARY OBJECTIVES: I. To determine the activity of a smoothened, frizzled class receptor (SMO) and PTCH1 inhibitor in patients with meningiomas harboring SMO mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring neurofibromin ...

Phase

3.87 miles

Learn More »

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer.

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

3.87 miles

Learn More »